Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 2
1991 1
1992 1
1993 2
1994 5
1996 3
1997 3
1998 4
1999 4
2000 9
2001 15
2002 21
2003 29
2004 36
2005 53
2006 70
2007 84
2008 48
2009 29
2010 27
2011 15
2012 9
2013 11
2014 9
2015 6
2016 8
2017 9
2018 6
2019 10
2020 9
2021 5
2022 5
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 17991293

499 results

Results by year

Filters applied: . Clear all
Page 1
Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
Oki Y, Ogura M, Kato H, Kikuchi A, Taji H, Kagami Y, Oshiro A, Tsujimura A, Yamamoto K, Morishima Y. Oki Y, et al. Cancer Sci. 2008 Jan;99(1):179-84. doi: 10.1111/j.1349-7006.2007.00662.x. Epub 2007 Nov 7. Cancer Sci. 2008. PMID: 17991293 Free article. Clinical Trial.
Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P, Passon J, Ebeling P, Welt A, Müller S, Metz K, Moritz T, Seeber S, Nowrousian MR. Schütt P, et al. Eur J Haematol. 2007 Feb;78(2):93-101. doi: 10.1111/j.1600-0609.2006.00796.x. Eur J Haematol. 2007. PMID: 17313557 Clinical Trial.
R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.
Martín A, Conde E, Arnan M, Canales MA, Deben G, Sancho JM, Andreu R, Salar A, García-Sanchez P, Vázquez L, Nistal S, Requena MJ, Donato EM, González JA, León A, Ruiz C, Grande C, González-Barca E, Caballero MD; Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL/TAMO Cooperative Group). Martín A, et al. Haematologica. 2008 Dec;93(12):1829-36. doi: 10.3324/haematol.13440. Epub 2008 Oct 22. Haematologica. 2008. PMID: 18945747 Free article.
499 results